Monoamine Transporters: From Genes To Behavior

Annual Review of Pharmacology and Toxicology

Volumn 43, Issue , 2003, Pages 261-284

  Gainetdinov, Raul R ^a   Caron, Marc G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Addiction; ADHD; Amphetamine; Cocaine; Knockout mice

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; CARRIER PROTEIN; COCAINE; DESIPRAMINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; GLUTAMATE RECEPTOR AGONIST; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE; MONOAMINE TRANSPORTER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTOXIN; NISOXETINE; NORADRENALIN; NORADRENALIN TRANSPORTER; POSTSYNAPTIC RECEPTOR; PSYCHOSTIMULANT AGENT; REBOXETINE; SEROTONIN; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANOXERINE; BIOGENIC AMINE;

ADDICTION; ANIMAL MODEL; ATTENTION DEFICIT DISORDER; BEHAVIOR; DOPAMINERGIC TRANSMISSION; GENE DOSAGE; GENETIC MODEL; HOMEOSTASIS; KNOCKOUT MOUSE; MOLECULAR GENETICS; MONOAMINERGIC SYSTEM; NEUROCHEMISTRY; NEUROMODULATION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRESYNAPTIC NERVE; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; REVIEW; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT; NERVE FIBER TRANSPORT; PHYSIOLOGY;

ANIMALIA;

ANIMALS; AXONAL TRANSPORT; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, KNOCKOUT;

EID: 0041350378     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.43.050802.112309     Document Type: Review

References (101)

1. Carlsson A. 1987. Perspectives on the discovery of central monoaminergic neurotransmission. Annu. Rev. Neurosci. 10:19-40
2. Greengard P. 2001. The neurobiology of slow synaptic transmission. Science 294:1024-30
3. Roth RH, Elsworth JD. 1995. Biochemical pharmacology of midbrain dopamine neurons. In Psychopharmacology: The Fourth Generation of Progress, ed. FE Bloom, DJ Kupfer, pp. 227-43. New York: Raven
4. Amara SG, Kuhar MJ. 1993. Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci. 16:73-93
5. Giros B, Caron MG. 1993. Molecular characterization of the dopamine transporter. Trends Pharmacol. Sci. 14:43-49
6. Uhl GR, Kitayama S. 1993. A cloned dopamine transporter. Potential insights into Parkinson's disease pathogenesis. Adv. Neurol. 60:321-24
7. Blakely RD, De Felice LJ, Hartzell HC. 1994. Molecular physiology of norepinephrine and serotonin transporters. J. Exp. Biol. 196:263-81
8. Reith MEA, Xu C, Chen N-H. 1997. Pharmacology and regulation of the neuronal dopamine transporter. Eur. J. Pharmacol. 324:1-10
9. Miller GW, Gainetdinov RR, Levey AI, Caron MG. 1999. Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 20:424-29
10. Nirenberg MJ, Chan J, Pohorille A, Vaughan RA, Uhl GR, et al. 1997. The dopamine transporter: comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens. J. Neurosci. 17:6899-907
11. Bunin MA, Wightman RM. 1999. Paracrine neurotransmission in the CNS: involvement of 5-HT. Trends Neurosci. 22:377-82
12. Schroeter S, Apparsundaram S, Wiley RG, Miner LH, Sesack SR, Blakely RD. 2000. Immunolocalization of the cocaine- and antidepressant-sensitive 1-norepinephrine transporter. J. Comp. Neurol. 420:211-32
13. Carboni E, Tanda GL, Frau R, Di Chiara G. 1990. Blockade of noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem. 55:1067-70
14. Cases O, Lebrand C, Giros B, Vitalis T, De Maeyer E, et al. 1998. Plasma membrane transporters of serotonin, dopamine, and norepinephrine mediate serotonin accumulation in atypical locations in the developing brain of monoamine oxidase A knock-outs. J. Neurosci. 18:6914-27
15. Pan Y, Gembom E, Peng W, Lesch KP, Mossner R, Simantov R. 2001. Plasticity in serotonin uptake in primary neuronal cultures of serotonin transporter knockout mice. Dev. Brain Res. 126:125-29
16. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT. 2002. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J. Neurosci. 22:389-95
17. Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, et al. 1996. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann. Neurol. 40:428-39
18. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, et al. 1996. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 2:699-703
19. Baumann MH, Ayestas MA, Rothman RB. 1998. Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats. J. Neurosci. 18:9069-77
20. Feenstra MG, Van Galen H, Te Riele PJ, Botterblom MH, Mirmiran M. 1996. Decreased hypothalamic serotonin levels in adult rats treated neonatally with clomipramine. Pharmacol. Biochem. Behav. 55:647-52
21. Avni J, Gerson S, Draskoczy PR, Schildkraut JJ. 1975. Norepinephrine content of various rat organs after chronic administration of desmethylimipramine. Arch. Int. Pharmacodyn. Ther. 218:106-9
22. Pugsley TA, Lippmann W. 1979. Effect of acute and chronic treatment of tandamine, a new heterocyclic antidepressant, on biogenic amine metabolism and related activities. Naunyn Schmiedebergs Arch. Pharmacol. 308:239-47
23. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. 1996. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-12
24. Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, et al. 1998. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol. Pharmacol. 53:649-55
25. Xu F, Gainetdinov RR, Wetsel WC, Jones SR, Bohn LM, et al. 2000. Mice lacking the norepinephrine transporter are super-sensitive to psychostimulants. Nat. Neurosci. 3:465-71
26. Gainetdinov RR, Sotnikova TD, Caron MG. 2002. Monoamine transporter pharmacology and mutant mice. Trends Pharmacol. Sci. 23:367-73
27. Gainetdinov RR, Mohn AR, Caron MG. 2001. Genetic animal models: focus on schizophrenia. Trends Neurosci. 24:527-33
28. Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, et al. 1998. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc. Natl. Acad. Sci. USA 95:7699-704
29. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. 1999. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283:397-401
30. Spielewoy C, Roubert C, Hamon M, Nosten-Bertrand M, Betancur C, Giros B. 2000. Behavioural disturbances associated with hyperdopaminergia in dopamine-transporter knockout mice. Behav. Pharmacol. 11:279-90
31. Bosse R, Fumagalli F, Jaber M, Giros B, Gainetdinov RR, et al. 1997. Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter. Neuron 19:127-38
32. Ralph RJ, Paulus MP, Fumagalli F, Caron MG, Geyer MA. 2001. Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonists. J. Neurosci. 21:305-13
33. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. 2001. Dopaminergic role in stimulant-induced wakefulness. J. Neurosci. 21:1787-94
34. Bliziotes M, McLoughlin S, Gunness M, Fumagalli F, Jones SR, Caron MG. 2000. Bone histomorphometric and biomechanical abnormalities in mice homozygous for deletion of the dopamine transporter gene. Bone 26:15-19
35. Walker JK, Gainetdinov RR, Mangel AW, Caron MG, Shetzline MA. 2000. Mice lacking the dopamine transporter display altered regulation of distal colonic motility. Am. J. Physiol. Gastrointest. Liver Physiol. 279:G311-18
36. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Caron MG. 1998. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc. Natl. Acad. Sci. USA 95:4029-34
37. Jones SR, Gainetdinov RR, Wightman RM, Caron MG. 1998. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18:1979-86
38. Benoit-Marand M, Jaber M, Gonon F. 2000. Release and elimination of dopamine in vivo in mice lacking the dopamine transporter: functional consequences. Eur. J. Neurosci. 12:2985-92
39. Gainetdinov RR, Jones SR, Fumagalli F, Wightman RM, Caron MG. 1998. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res. Rev. 26:148-53
40. Gainetdinov RR, Jones SR, Caron MG. 1999. Functional hyperdopaminergia in dopamine transporter knock-out mice. Biol. Psychiatry 46:303-11
41. Jaber M, Dumartin B, Sagne C, Haycock JW, Roubert C, et al. 1999. Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. Eur. J. Neurosci. 11:3499-511
42. Seeman P. 1980. Brain dopamine receptors. Pharmacol. Rev. 32:229-313
43. Jones SR, Gainetdinov RR, Hu X-T, Cooper DC, Wightman RM, et al. 1999. Loss of autoreceptor functions in mice lacking the dopamine transporter. Nat. Neurosci. 2:649-55
44. Fauchey V, Jaber M, Caron MG, Bloch B, Le Moine C. 2000. Differential regulation of the dopamine D1, D2 and D3 receptor gene expression and changes in the phenotype of the striatal neurons in mice lacking the dopamine transporter. Eur. J. Neurosci. 12:19-26
45. Cooper DC, Hu X-T, Jones SR, Giros B, Caron MG, White FJ. 1997. In vivo neurophysiological assessment of mesoaccumbens dopamine function in dopamine transporter knockout mice. Soc. Neurosci. 23:1210 (Abstr.)
46. Zhuang X, Oosting RS, Jones SR, Gainetdinov RR, Miller GW, et al. 2001. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc. Natl. Acad. Sci. USA 98:1982-87
47. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI. 1998. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J. Neurosci. 18:2697-708
48. Garris PA, Wightman RM. 1994. Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J. Neurosci. 14:442-50
49. Bannon MJ, Freeman AS, Chiodo LA, Bunney BS, Roth RH. 1987. The pharmacology and electrophysiology of mesolimbic dopamine neurons. In Handbook of Psychopharmacology, ed. LL Iversen, 19:329-74. New York: Plenum
50. Kilts CD, Anderson CM, Ely TD, Nishita JK. 1987. Absence of synthesis modulating nerve terminal autoreceptors on mesoamygdaloid and other mesolimbic dopamine neuronal populations. J. Neurosci. 7:3961-75
51. Moghaddam B, Roth RH, Bunney BS. 1990. Characterization of dopamine release in the rat medial prefrontal cortex as assessed by in vivo microdialysis: comparison to the striatum. Neuroscience 36:669-76
52. Vizi ES. 2000. Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in the central nervous system. Pharmacol. Rev. 52:63-89
53. Patel AP, Cerruti C, Vaughan RA, Kuhar MJ. 1994. Developmentally regulated glycosylation of dopamine transporter. Dev. Brain. Res. 83:53-58
54. Jones SR, Bowman BP, Kuhn CM, Wightman RM. 1996. Development of dopamine neurotransmission and uptake inhibition in the caudate nucleus as measured by fast-cyclic voltammetry. Synapse 24:305-7
55. Bannon MJ, Poosch MS, Xia Y, Goebel DJ, Cassin B. 1992. Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. Proc. Natl. Acad. Sci. USA 89:7095-99
56. Xia Y, Goebel DJ, Kapatos G, Bannon MJ, Kapatos G. 1992. Quantification of rat dopamine transporter mRNA: effects of cocaine treatment and withdrawal. J. Neurochem. 59:1179-82
57. Rocha BA, Fumagalli F, Gainetdinov RR, Jones SR, Ator R, et al. 1998. Cocaine self-administration in dopamine transporter knockout mice. Nat. Neurosci. 1:132-37
58. Seiden LS, Sabol KE, Ricaurte GA. 1993. Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 33:639-77
59. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A. 1995. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15:4102-8
60. Seiden LS, Sabol KE. 1995. Neurotoxicity of methamphetamine-related drugs and cocaine. In Handbook of Neurotoxicology, ed. LW Chang, RS Dyer, pp. 825-43. New York: Marcell Dekker
61. Fumagalli F, Gainetdinov RR, Valenzano KJ, Caron MG. 1998. Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J. Neurosci. 18:4861-69
62. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG. 1997. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69:1322-25
63. Bezard E, Gross CE, Fournier MC, Dovero S, Bloch B, Jaber M. 1999. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurol. 155:268-73
64. Wise RA. 1996. Neurobiology of addiction. Curr. Opin. Neurobiol. 6:243-51
65. Kuhar MJ. 1992. Molecular pharmacology of cocaine: a dopamine hypothesis and its implications. Ciba Found. Symp. 166:81-89
66. Carboni E, Spielewoy C, Vacca C, Nosten-Bertrand M, Giros B, Di Chiara G. 2001. Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. J. Neurosci. 21:RC141, 1-4
67. Budygin EA, John CE, Mateo Y, Jones SR. 2002. Lack of cocaine effect on dopamine clearance in the core and shell of the nucleus accumbens of dopamine-transporter knockout mice. J. Neurosci. 22:RC222, 1-4
68. Cunningham KA, Bradberry CW, Chang AS, Reith ME. 1996. The role of serotonin in the actions of psychostimulants: molecular and pharmacological analyses. Behav. Brain Res. 73:93-102
69. Sora I, Hall FS, Andrews AM, Itokawa M, Li XF, et al. 2001. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc. Natl. Acad. Sci. USA 98:5300-5
70. Spielewoy C, Biala G, Roubert C, Hamon M, Betancur C, Giros B. 2001. Hypolocomotor effects of acute and daily d-amphetamine in mice lacking the dopamine transporter. Psychopharmacology (Berl.) 159:2-9
71. Hollister AS, Breese GR, Kuhn CM, Cooper BR, Schanberg SM. 1976. An inhibitory role for brain serotonin-containing systems in the locomotor effects of d-amphetamine. J. Pharmacol. Exp. Ther. 198:12-22
72. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. 2001. Interaction between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu. Rev. Pharmacol. Toxicol. 41:237-60
73. Gainetdinov RR, Mohn AR, Bohn LM, Caron MG. 2001. Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proc. Natl. Acad. Sci. USA 98:11047-54
74. Klitenick MA, Atkinson BN, Baker DA, Bakker M, Bell SC, et al. 2001. Development and characterization of GLYT1-selective glycine reuptake inhibitors. Presented at Ann. Meet. Am. Coll. Neuropsychopharmacology, 40th, Waikoloa, Hawaii
75. Spielewoy C, Gonon F, Roubert C, Fauchey V, Jaber M, et al. 2000. Increased rewarding properties of morphine in dopamine-transporter knockout mice. Eur. J. Neurosci. 12:1827-37
76. Barkley RA, ed. 1990. Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. NY: Guiford
77. Popper CW. 1997. Antidepressants in the treatment of attention-deficit/hyperactivity disorder. J. Clin. Psychiatry 58(Suppl. 14):14-29
78. Cook EH Jr, Stein MA, Krasowski MD, Cox NJ, Olkon DM, et al. 1995. Association of attention-deficit disorder and the dopamine transporter gene. Am. J. Hum. Genet. 56:993-98
79. Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M. 1997. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol. Psychiatry 2:311-13
80. Waldman ID, Rowe DC, Abramowitz A, Kozel ST, Mohr JH, et al. 1998. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am. J. Hum. Genet. 63:1767-76
81. Gainetdinov RR, Caron MG. 2000. An animal model of attention deficit hyperactivity disorder. Mol. Med. Today 6:43-44
82. Gainetdinov RR, Caron MG. 2001. Genetics of childhood disorders: XXIV. ADHD, part 8: hyperdopaminergic mice as an animal model of ADHD. J. Am. Acad. Child. Psychiatry 40:380-82
83. Donovan DM, Miner LL, Perry MP, Revay RS, Sharpe LG, et al. 1999. Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. Mol. Brain Res. 73:37-49
84. D'Amato RJ, Blue ME, Largent BL, Lynch DR, Ledbetter DJ, et al. 1987. Ontogeny of the serotonergic projection to rat neocortex: transient expression of a dense innervation to primary sensory areas. Proc. Natl. Acad. Sci. USA 84:4322-26
85. Ujike H, Tsuchida K, Akiyama K, Fujiwara Y, Kuroda S. 1995. Ontogeny of behavioral sensitization to cocaine. Pharmacol. Biochem. Behav. 50:613-17
86. Chen JJ, Li Z, Pan H, Murphy DL, Tamir H, et al. 2001. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J. Neurosci. 21:6348-61
87. Rattray M. 1991. Ecstasy: towards an understanding of the biochemical basis of the actions of MDMA. Essays Biochem. 26:77-87
88. Uhl GR, Hall FS, Sora I. 2002. Cocaine, reward, movement and monoamine transporters. Mol. Psychiatry 7:21-26
89. Murphy DL, Wichems C, Andrews AM, Li Q, Hamer D, Greenberg BD. 1999. Consequences of engineered and spontaneous genetic alterations of the 5-HT transporter in mice, men and women. Behav. Pharmacol. 10(Suppl. 1):S65
90. Fabre V, Beaufour C, Evrard A, Rioux A, Hanoun N, et al. 2000. Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors in knock-out mice lacking the 5-HT transporter. Eur. J. Neurosci. 12:2299-310
91. Gobbi G, Murphy DL, Lesch, KP, Blier P. 2001. Modifications of the serotonergic system in mice lacking serotonin transporters: an in vivo electrophysiological study. J. Pharmacol. Exp. Ther. 296:987-95
92. Li Q, Wichems C, Heils A, Van De Kar LD, Lesch KP, Murphy DL. 1999. Reduction of 5-hydroxytryptamine (5-HT)(1A)-mediated temperature and neuroendocrine responses and 5-HT(1A) binding sites in 5-HT transporter knockout mice. J. Pharmacol. Exp. Ther. 291:999-1007
93. Rioux A, Fabre V, Lesch KP, Moessner R, Murphy DL, et al. 1999. Adaptive changes of serotonin 5-HT2A receptors in mice lacking the serotonin transporter. Neurosci. Lett. 262:113-16
94. Wang YM, Xu F, Gainetdinov RR, Caron MG. 1999. Genetic approaches to studying norepinephrine function: knockout of the mouse norepinephrine transporter gene. Biol. Psychiatry 46:1124-30
95. Bohn LM, Xu F, Gainetdinov RR, Caron MG. 2000. Potentiated opioid analgesia in norepinephrine transporter knock-out mice. J. Neurosci. 20:9040-45
96. Willner P. 1997. The mesolimbic dopamine system as a target for rapid antidepressant action. Int. Clin. Psychopharmacol. 12(Suppl 3):S7-14
97. Mundorf ML, Joseph JD, Austin CM, Caron MG, Wightman RM. 2001. Catecholamine release and uptake in the mouse prefrontal cortex. J. Neurochem. 79:130-42
98. Miles PR, Mundorf ML, Wightman RM. 2002. Release and uptake of catecholamines in the bed nucleus of the stria terminalis measured in the mouse brain slice. Synapse 44:188-97
99. Agnati LF, Zoli M, Stromberg I, Fuxe K. 1995. Intercellular communication in the brain: wiring versus volume transmission. Neuroscience 69:711-26
100. Carroll FI, Rahman MA, Philip A, Lewin AH, Boja JW, Kuhar MJ. 1991. Synthesis and receptor binding of cocaine analogs. NIDA Res. Monogr. 105:147-53
101. Freeman WM, Yohrling GJ, Daunais JB, Gioia L, Hart SL, et al. 2000. A cocaine analog, 2beta-propanoyl-3beta-(4-tolyl)-tropane (PTT), reduces tyrosine hydroxylase in the mesolimbic dopamine pathway. Drug Alcohol Depend. 61:15-21